A Better Tomorrow with HanAll
Innovative Therapeutics to Address Unmet Medical Needs of Patients
Developing Innovations for Healthier,
Longer lives for Patients
Committed to Pioneering Next
HanAll Biopharma’s Partner, NurrOn Pharmaceuticals Incorpora..
Woburn, MA – December 11, 2023 HanAll Biopharma’s partner NurrOn Pharmaceutic..
HanAll Biopharma Reports Third Quarter 2023 Financial Result..
- Sales recorded KRW 33 billion in Q3 2023, an 11 percent increase from the sam..
HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmac..
- HanAll Biopharma and Daewoong Pharmaceutical marked a pivotal step forward in..
HanAll Biopharma Reports Second Quarter 2023 Financial Resul..
l Sales recorded KRW 41.4 billion, a 58 percent increase from the same period i..
HanAll Biopharma and Daewoong Pharmaceutical Co-invest in Vi..
- HanAll Biopharma and Daewoong Pharmaceutical have co-invested in Vincere Biosc..
HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-D..
- HanAll Biopharma and Daewoong Pharmaceutical will co-develop NurrOn Pharmaceut..
HanAll Biopharma, Conclusion of Joint Development Contract f..
HanAll Biopharma and Daewoong Pharmaceutical have announced that they have conc..